Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.

NCT02141516 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
239
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Novartis

Collaborators